Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer

Inclusion Criteria:

- Histologically proven prostate adenocarcinoma

- Clinical stage T1a-T3, N0-Nx, M0-Mx

- Patients belonging in one of the following risk groups: (1) LOW RISK: CS T1a-T2a,
Gleason 2-6, PSA<10, Nx-0, Mx-0; (2) INTERMEDIATE RISK: CS T2b, Gleason ≤7, PSA<20,
Nx-0, Mx-0, or CS T1a-T2b, Gleason 2-6, PSA≥10 & <20, Nx-0, Mx-0, or CS T1a-T2b,
Gleason 7, PSA≤20, Nx-0, Mx-0; or (3) HIGH RISK: CS T2c-T3, any Gleason, any PSA, or
CS T1-3, Gleason ≥8 and/or PSA≥20

- Karnofsky performance status 70-100

- Hormone therapy: includes LHRH agonists (e.g. leuprolide, goserelin, triptorelin),
antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide,
nilutamide), estrogens (e.g. DES) and bilateral orchiectomy

- Low and Intermediate risk groups: no hormone ablation for two months prior to
enrollment, or during treatment

- High risk group: three hormone therapy regimens are allowed

- 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are allowed

Exclusion Criteria:

- Prior prostatectomy or cryotherapy of the prostate

- Prior high-dose radiotherapy to the prostate or lower pelvis

- Implanted hardware or other material that would prohibit appropriate treatment
planning or treatment delivery, in the investigator's opinion